The historical rank and industry rank for Neuland Laboratories's Days Payable or its related term are showing as below:
NSE:NEULANDLAB'
s Days Payable Range Over the Past 10 Years
Min: 85.75 Med: 92.3 Max: 119.94
Current: 104.2
During the past 13 years, Neuland Laboratories's highest Days Payable was 119.94. The lowest was 85.75. And the median was 92.30.
NSE:NEULANDLAB's Days Payable is ranked better than 58.04% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs NSE:NEULANDLAB: 104.20
Neuland Laboratories's Days Payable
declined
from Mar. 2025 (133.81) to Mar. 2026 (76.51).
It may suggest that Neuland Laboratoriesaccelerated paying its suppliers.
Neuland Laboratories Days Payable Related Terms
Neuland Laboratories Days Payable Historical Data
* Premium members only.
The historical data trend for Neuland Laboratories's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Neuland Laboratories's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuland Laboratories Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neuland Laboratories's Days Payable distribution charts can be found below:
* The bar in red indicates where Neuland Laboratories's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Neuland Laboratories's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuland Laboratories (NSE:NEULANDLAB) has a Days Payable of 76.51 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Neuland Laboratories and its competitors. This is 17% below median its historical median of 92.30. Over the past decade, Neuland Laboratories' Days Payable has ranged from 85.75 to 119.94. According to the industry distribution chart, Neuland Laboratories ranks #386 out of 920 companies in the Drug Manufacturers industry, placing it in the top 42%.
Is Neuland Laboratories' Days Payable too high?
Neuland Laboratories' current Days Payable of 76.51 is 17% below median its 10-year median of 92.30. Over the past 10 years, this metric has ranged from a low of 85.75 to a high of 119.94. The Drug Manufacturers industry median Days Payable is 90.84. Neuland Laboratories' value of 76.51 is 15.8% below this industry median. Based on the distribution chart, Neuland Laboratories ranks #386 out of 920 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Neuland Laboratories has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neuland Laboratories' Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Neuland Laboratories ranks #386 out of 920 companies for Days Payable. This puts Neuland Laboratories in the upper half of its industry. The industry median Days Payable is 90.84. Neuland Laboratories' value of 76.51 is 15.8% below this benchmark. Historically, Neuland Laboratories' own Days Payable has ranged from 85.75 to 119.94 over the past decade. While the company's 10-year median is 92.30 vs. the industry median of 90.84, Neuland Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuland Laboratories's current Days Payable of 76.51 is 15.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Neuland Laboratories and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuland Laboratories's current Days Payable is 76.51, which is 17% below median its own 10-year median of 92.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuland Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Neuland Laboratories (NSE:NEULANDLAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹16,471.48, compared to a current price of ₹17,961.00 — trading 9% above its estimated fair value. The current Days Payable is 76.51, which is 17% below median its 10-year median of 92.30 and 15.8% below the Drug Manufacturers industry median of 90.84. Neuland Laboratories' overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Neuland Laboratories (NSE:NEULANDLAB), the current Days Payable is 76.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuland Laboratories (NSE:NEULANDLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Neuland Laboratories stock appears to be overvalued.
The current stock price of ₹17,961.00 is trading 9% above its estimated GF Value™ of ₹16,471.48.
GuruFocus considers Neuland Laboratories to be Fairly Valued.
Key valuation signals for NSE:NEULANDLAB:
Days Payable: 76.51 (17% below median its 10-year median of 92.30)
GF Value™: ₹16,471.48 vs. price of ₹17,961.00 (9% above fair value)
Industry Position: 15.8% below the Drug Manufacturers median (#386 of 920)
No single metric tells the full story. See the NSE:NEULANDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
90GF Score
Get the complete analysis for NSE:NEULANDLAB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NEULANDLAB has been successfully added to your 
